Revenio Group Oyj
LSE:0KFH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Revenio Group Oyj
LSE:0KFH
|
FI |
|
Fabasoft AG
LSE:0IWU
|
AT |
|
D
|
Devon Energy Corp
LSE:0I8W
|
US |
|
Sulzer AG
LSE:0QQ9
|
CH |
|
Rightscorp Inc
OTC:RIHT
|
US |
Revenio Group Oyj
Revenio Group Oyj is a globally operating health technology, which engages in the detection of glaucoma, osteoporosis, skin cancer, and asthma. The company is headquartered in Vantaa, Etela-Suomen and currently employs 184 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
Revenio Group Oyj is a globally operating health technology, which engages in the detection of glaucoma, osteoporosis, skin cancer, and asthma. The company is headquartered in Vantaa, Etela-Suomen and currently employs 184 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
Revenue: Q1 net sales were EUR 27.3 million, up 4.8% reported and 8.4% currency-adjusted, with especially strong growth in the U.S. and Europe.
Profitability: Reported operating profit fell to EUR 2.4 million, mainly because of about EUR 3.1 million in Visionix transaction-related costs and other one-off items; adjusted operating profit was 21.3% of sales.
Outlook: The company withdrew prior guidance and said it will return with an updated outlook after the Visionix transaction closes.
Visionix Deal: Management said the April 13 deal expands the addressable market from USD 1 billion to USD 2.5 billion and adds OCT, broader customer coverage, and expected synergies.
Balance Sheet: The first quarter cash flow was weak, but management said the balance sheet remains unlevered for now and will become more leveraged at closing before a planned rights issue later in the year.
Margins: Gross margin was pressured by tariffs, mix, and FX, though management said price increases started in February and should help improve the margin over time.
